Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
price now 275 GL
UPDATE - TyraTech hails US launch of Novartis-backed livestock product By Ian Lyall April 30 2014, 12:01pm Road map to success: TyraTech has announced the US launch of Natunex. The milestones are coming thick and fast for TyraTech (LON:TYR), the specialist in nature-derived insect and parasite control products. This morning the group announced the US launch of Natunex, a new line of non-toxic biocides that provides highly effective and fast insect control in livestock. The product will be distributed by Novartis Animal Health in the States, and taps both companies into a market predicted to be worth US$1bn by 2016. Chief executive Bruno Jactel said: "TyraTech is excited about delivering the Natunex product line, which addresses the increased demand from livestock producers for efficacious, safe and more practical solutions to control insects and parasites. “The partnership with Novartis Animal Health will make Natunex immediately available across Novartis' network of US livestock producers, with a global roll-out forthcoming. “In addition, this relationship demonstrates the effectiveness and quality of TyraTech's technology and products. Natunex represents a significant step forward in non-toxic, environmentally friendly and highly effective pest control." The announcement reveals it is business as usual for the Swiss drugs giant, which is in the formative stages of a sale of its animal health unit to Eli Lilly. It is just one of a series of announcements that show TyraTech is turning its early promise into commercial reality. At the end of last month its Vamousse treatment for head lice went on sale in 4,000 Wal-Mart stores. Vamousse and Natunex are just two of a number of natural oil-based products lined up for the US market. These include a preventative shampoo for head lice to follow Vamousse that it hopes will transform the market by switching the emphasis to prevention rather than treatment. Another new product is a natural oil-based repellent for mosquitoes and ticks. The personal repellent market is worth about US$200mln and dominated by products based on DEET, a pesticide developed by the Americans for the Vietnam War.
April 01 2014, 2:50pm TyraTech is aiming for a significant market share, as competing products are long in the tooth and do not receive much marketing support. TyraTech’s (LON:TYR) treatment for head lice has already hit shelves in over 4,000 Walmart stores in the US, the AIM-listed company has revealed. The retail giant has stocked all of its US stores with Vamousse, which is said to be safer and more effective than traditional treatments. Bruno Jactel, chief executive of the natural insecticide group, said: “The board is very pleased that we are currently on schedule both in terms of number of stores and timings of sales for our Vamousse head lice treatment, with products already selling in the USA. “We are confident this roll-out will greatly raise the profile of Vamousse.” Speaking to Proactive Investors, Jactel said the company remains in discussions with numerous other retailers interested in stocking its products, but is largely focusing on making the Wal-Mart roll-out a success at the moment. In September of last year the company revealed it has reached a preliminary distribution agreement for 2014 to place TyraTech's head lice product with a major pharmacy chain in the USA, representing around 8,500 pharmacy stores or close to 15% of retail pharmacy stores in the USA The company is supporting the launch of Vamousse in the US with a “very strong marketing campaign”, Jactel revealed, combining “clear information to the mums as well as to the [medical] professionals”. “We are working in a category where the current competitors are not really investing in marketing – their products being very old, and maybe [regarded as] cash cows,” Jactel said. TyraTech’s products are based on natural essential oils that act against pests but have no effect on humans. Its products focus on personal care, which includes the head lice treatments, animal health and household, agricultural and garden insecticides.
masterswordsman ....Well now you know that I can" copy and paste " and we now know that you can predict the future . Funny I missed the part where you wrote that all shares will be down today because of what is going on in Ukraine !
I am sure that all who are invested here thank you for your concern. But it seems that you are not really up to date on RM2. It might help if you read about it than you might follow Invesco Perpetual and invest in it. ps. they did say who they signed the contracts with , there might be others this are just the big names. ............... It will be quoted on Aim and valued at £278 million. RM2 has already raised £137 million cash to expand its production capacity and fund the manufacture of pallets to rent and sell. We are very encouraged by the fact that none of the existing shareholders are selling down their holdings at flotation. Invesco Perpetual is the biggest investor and management also has a significant position. RM2 says ‘dozens’ of blue chip companies are already using the new pallets, notably Heinz (HNZ:NYSE), IBM (IBM:NYSE), Flextronics (FLEX:NDQ) and Unilever (ULVR). RM2 claims its pallet costs $55 to make and last for more than 100 trips. Walsh says normal wooden pallets cost $40 each and only survive 30 stints on average. ‘You can get low-quality wood single-use versions for as little as $6 but these are an environmental disaster as they go into landfill.’ Its Canadian plant can produce one million pallets a year. RM2 will increase capacity to three million units in 2014, helped by the launch of a new factory in the US. The following year should see a UK plant open and annual production capacity reach 6.5 million pallets. North America and Western Europe are the target markets. Board members have significant contacts in the food, drink, retail and private equity sectors. Chairman Ian Molson is former deputy chairman of Canadian brewer Molson. Non-executive directors include former Marks & Spencer (MKS) chairman Stuart Rose; and Paul Walsh who is ex-CEO of Diageo (DGE) and incoming chairman of catering giant Compass (CPG).
Canaccord Genuity stuck to its ‘buy’ tag for Silence Therapeutics (LON:SLN), the company behind a gene silencing technology. The broker said: “A safety update from the Atu027 Phase IIa pancreatic cancer clinical trial is due in H2014, this should validate the platform technology and increase interest from potential partners. “Continued clinical, commercial and financial activity in the sector should also support the shares.”
I was not referring to those who will sell after 1 year but of those who will migrate now.
You have to realise that when TYR shares are migrated to TYRU you will not get the same amount of shares because the share price of both shares is different . So you are bound to get less shares
TYR are restricted shares and can only be bought in certified form. TYRU can be traded through CREST so the market in them is better.
(a) Lansdowne Oil & Gas plc The Company currently holds a 21.48 per cent interest in Lansdowne which is itself AIM listed. Lansdowne holds extensive acreage including a 20 per cent interest in the recent Barryroe oil discovery in the Celtic Sea off the south coast of Ireland. Further details can be found on their website. www.lansdowneoilandgas.com
is the shaare to buy the other TYR is restricted. That means it will prove difficult to sell
There is no UK part or US part . It is the same company. Only the shares trade dofferently.
TYRU are traded via Crest you will not get a certificate TyraTech currently has 168,776,305 common share in issue of which 1,084,413 are held in Treasury. The number of restricted common shares trading under TIDM 'TYR' is 117,352,576 and the number of unrestricted common shares trading under TIDM 'TYRU' is 51,423,729. Settlement of shares trading under "TYRU" is available via CREST.
can anyone explain the differemce between TYRU and TYR please ?
how very true, I am down with the flu !!
Can you print the article ? You have to be a subscriber to be able to read it.
This stock won’t start trading until January 6. But RM2, which makes the pallets used in their billions by retailers and many other businesses every day, looks like it has a bright future. Rather than traditional wooden pallets, RM2 makes, sells and rents its BLOCKPal version made out of glass fibre and resin composite. The advantage is that they are more durable, less likely to damage goods, easier to make in bespoke shapes and can easily be fitted with tracking devices to improve logistics. They also help firms meet environmental sustainability targets. RM2 produces 1m pallets a year at the moment and says it can get to 2.5m next year with the £137.2m proceeds of its float, and 7m by 2015. Management thinks US customers want to extend contracts to European and Asian subsidiaries. They also think RM2 will not need to raise equity again. Sir Stuart Rose and former Diageo boss Paul Walsh are on the board. It is chaired by Ian Molson, former deputy chairman of the Canadian brewing giant. *** It does say 1M *** Read more: http://www.thisismoney.co.uk/money/markets/article-2530313/Top-share-tips-2014-Daily-Mail-City-team.html#ixzz2qbNzqEwJ Follow us: @MailOnline on Twitter | DailyMail on Facebook
Like you I can see nothing wrong with this company. People are not realising that this is a "new listing ". Given chance , even one month , I am sure that some news will be given
Mon, 13th Jan 2014 14:48 RNS Number : 5277X RM2 International SA 13 January 2014 RM2 International S.A. Director / PDMR Shareholding RM2 International S.A. ("RM2" or the "Company") announces that it was notified on 10 January 2014 that The Swiftsure Trust, a discretionary trust of which the principal beneficiaries are the children of Ian Molson, Chairman of RM2, acquired 500,000 ordinary shares in the company ("Ordinary Shares") at a price of 93.58 pence per ordinary share on that date. Following this transaction, Mr Molson is interested in a total of 4,451,340 Ordinary Shares, representing approximately 1.4 per cent. of the existing issued share capital of the Company.
RM2′s strong IPO debut Pallet manufacturer and rental group RM2 International (RM2:AIM) makes an impressive stockmarket debut with a 20% rise to 105.5p. The group has raised £137.2 million to help increase its production capacity and have a pool of pallets to rent to customers in such sectors as food, drink, pharmaceuticals and technology. RM2 has developed a new form of pallets that it claims are more robust and last longer than traditional wood products. There’s big names on the board including former Marks & Spencer (MKS) boss Stuart Rose, Paul Walsh who is ex-chief executive of Diageo (DGE) and incoming chairman of catering group Compass (CPG). RM2′s chief executive John Walsh (pictured above) is a former investment banker. We published a swot analysis on the stock and fleshed out its growth plans in last week’s issue of Shares, saying to buy the shares on day one. We like the company’s strong cash position, big customer names and well-connected board. As we highlight in the article, longer-term this could be an attractive dividend stock because of the significant cash flow potential from pallet rental agreements. You’ll need to be a subscriber to read the full story. Those not already signed up can get an introductory offer via this link. The business raised cash at 88p. Today’s share price rise means RM2 is now valued at £334 million. The Daily Mail has picked RM2 as one of its top share tips for 2014. Date: 06-01-2014 09:32